CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignancies
Sign Up to like & getrecommendations! Published in 2021 at "Leukemia Research Reports"
DOI: 10.1016/j.lrr.2021.100268
Abstract: CD47 is a surface glycoprotein expressed by host cells to impede phagocytosis upon binding to macrophage SIRPα, thereby represents an immune checkpoint known as the “don't-eat-me” signal. However, accumulating evidence shows that solid and hematologic… read more here.
Keywords: cd47 targeting; strategy hematologic; therapeutic strategy; targeting antibodies ... See more keywords
Emerging Proteolysis Targeting Antibodies (PROTABs) for Application in Cancer Therapy.
Sign Up to like & getrecommendations! Published in 2022 at "ACS medicinal chemistry letters"
DOI: 10.1021/acsmedchemlett.2c00458
Abstract: The emerging proteolysis targeting antibodies (PROTABs) offer an attractive technology that circumvents some of the challenges of small-molecule intracellular degraders with limited bioavailability and cell permeability. PROTABs present an improved approach to target degradation of… read more here.
Keywords: antibodies protabs; emerging proteolysis; protabs application; targeting antibodies ... See more keywords
Therapeutic CD20-Targeting Antibodies Differ in Their Binding Modes.
Sign Up to like & getrecommendations! Published in 2020 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2020-122
Abstract: Type I and II antibodies bound CD20 with different stoichiometry and recognized different epitopes. read more here.
Keywords: cd20 targeting; differ binding; binding modes; antibodies differ ... See more keywords